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BACKGROUND	AND	OBJECTIVES	
	
Currently,	more	than	80%	of	children	with	acute	lymphoblasOc	leukemia	(ALL)	can	be	cured	through	
intensive	 and	 risk-oriented	 chemotherapy	 protocols.	 Allogeneic	 hematopoieOc	 stem	 cell	
transplantaOon	(HSCT)	is	considered	beneﬁcial	for	approximately	10%	of	the	paOents	who	are	at	very-
high	risk	at	frontline	therapy	and	for	the	majority	of	paOents	aYer	relapse.	Consequently,	it	is	criOcally	
important	to	idenOfy	prognosOc	factors	in	this	group	of	paOents	in	order	to	tailor	risk-adapted	therapy.		
In	this	retrospecOve	study,	we	aimed	to	assess	the	prognosOc	role	of	minimal	residual	disease	(MRD)	
before	HSCT	and	at	diﬀerent	Ome	points	aYer	transplantaOon	in	children	with	ALL.	
	
PATIENTS	AND	METHODS	
	
We	analyzed	64	pediatric	ALL	paOents	given	HSCT:	22/64	were	in	ﬁrst	complete	remission	(1CR)	and	
42/64	in	second	complete	remission	(2CR).	Genomic	DNA	was	obtained	from	bone	marrow	aspirates	
collected	at	diagnosis/relapse,	before	HSCT	(pre-HSCT)	and	at	the	ﬁrst	and	third	trimesters	aYer	HSCT	
(post-HSCT1	 and	 post-HSCT3).	 MRD	 was	 measured	 by	 quanOtaOve	 real-Ome	 PCR	 assays	 based	 on	
paOent-speciﬁc	 juncOonal	 regions	 and	 interpreted	 according	 to	 the	 EuroMRD	 guidelines	 (Fig.1).	 The	
associaOon	between	MRD	and	survival	was	assessed	by	chi-square	test.	
Fig.1	 	AmpliﬁcaOon	plots	of	RQ-PCR	assay	in	paOent	TMO63	(relapse	S4).	Panel	A	shows	the	standard	curve	e	il	
QuanOtaOve	Range	 (1.0E-04);	 panel	B	 shows	 the	MRD	 results	 for	pre-HSCT	 (8.5E-04),	 post-HSCT1	 (<1.0E-04)	 e	
post-HSCT3	(1.0E-01);	panel	C	represents	the	albumin	housekeeping	gene	ampliﬁcaOon.	
	
RESULTS	
	
All	evaluated	paOents	were	analyzed	for	MRD	before	transplantaOon	(pre-HSCT).	MRD	was	negaOve	
in	26/64	paOents	and	posiOve	in	38/64	paOents.	As	for	cases	with	posiOve	MRD,	17/38	showed	MRD	
levels	 ≥1x10-3	 and	 21/38	 <1x10-3.	 Any	 detectable	 MRD	 posiOvity	 at	 pre-HSCT	 was	 signiﬁcantly	
associated	with	 a	 poor	 prognosis:	 28/38	 paOents	with	 posiOve	MRD	 are	 dead,	whereas	 22/26	with	
negaOve	MRD	are	alive	in	CR	(P	<	0.001)	(Fig.2).	
Among	the	42	paOents	in	2CR,	14/42	had	negaOve	pre-HSCT	MRD	and	28/42	were	MRD	posiOve.	The	
negaOvity	 of	 MRD	 before	 transplantaOon	 was	 found	 to	 be	 signiﬁcantly	 associated	 with	 a	 good	
prognosis:	13/14	paOents	with	negaOve	MRD	are	alive	in	CR,	while	23/28	with	posiOve	MRD	are	dead	
(p	<	0.001)	(Fig.	3).	
						Fig.2	Outcome	according	to	pre-HSCT	MRD.													Fig.3	Outcome	according	to	pre-HSCT	MRD	in	2CR	paOents.	
	
Post-HSCT1	 MRD	 was	 analyzed	 in	 53	 paOents:	 17/53	 were	 MRD	 posiOve	 and	 36/53	 were	 MRD	
negaOve.	Based	on	MRD	status,	the	prognosis	was	signiﬁcantly	diﬀerent:	26/36	paOents	with	negaOve	
post-HSCT1	MRD	are	alive	 in	CR,	whereas	14/17	of	paOents	with	posiOve	MRD	are	dead	 (P	<	0.001)	
(Fig.4).		
Post-HSCT3	MRD	was	assessed	 in	41	paOents	 and	19/41	were	 found	posiOve.	 Persistence	of	MRD	
was	associated	with	a	poor	prognosis	also	at	this	Ome-point	(P	=	0.001)	(Fig.	5).	
						Fig.4	Outcome	according	to	post-HSCT1	MRD.																								Fig.5	Outcome	according	to	post-HSCT3	MRD.	
	
CONCLUSIONS	
	
These	results	conﬁrm	that	MRD	assessment	has	a	criOcal	role	both	before	and	aYer	transplantaOon.	
NegaOve	MRD	before	transplantaOon	is	strongly	associated	with	a	good	prognosis,	parOcularly	in	2CR	
paOents.	Since	persistence	of	MRD	aYer	HSCT	is	signiﬁcantly	associated	with	a	worse	outcome,	these	
paOents	could	beneﬁt	from	early	disconOnuaOon	of	 immunosuppression,	adopOve	T-cell	therapy	and	
the	use	of	new	drugs.	
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